Showing 3941-3950 of 9083 results for "".
- Long-term Upadacitinib Data Show Low Rates of MACE, Malignancyhttps://practicaldermatology.com/news/low-rates-of-mace-malignancy-observed-with-upadacitinib-over-6-years/2486427/Long-term safety data from three phase 3 trials (Measure Up 1, Measure Up 2, and AD Up) provided a 6-year view of upadacitinib in moderate-to-severe atopic dermatitis (AD) stratified across multiple age groups. A total of 2,68
- MG-K10 Shows Sustained Efficacy in Atopic Dermatitis Through 52 Weekshttps://practicaldermatology.com/news/mg-k10-shows-sustained-efficacy-in-atopic-dermatitis-through-52-weeks/2486421/A long-acting anti–IL-4 receptor alpha monoclonal antibody, MG-K10, demonstrated sustained efficacy and a favorable safety profile through 52 wee
- Study Links MRGPRX3 Expression to Chronic Pruritus in PN and ADhttps://practicaldermatology.com/news/study-links-mrgprx3-expression-to-chronic-pruritus-in-pn-and-ad/2486413/In a prospective analysis of skin biopsies, investigators reported significantly elevated cutaneous MRGPRX3 expression in lesional prurigo nodularis (PN) and atopic dermatitis (AD), alongside a notable association between MRGPRX3-related gene mutations and Black pa
- Air Pollution Linked to Increased Psoriasis Burden: Meta-Analysishttps://practicaldermatology.com/news/air-pollution-linked-to-increased-psoriasis-burden-meta-analysis/2486409/New research presented at AAD 2026 suggests airborne pollutant particulate matter less than 2.5 microns in diameter (PM2.5), PM10, and NO2 showed the most consistent positive associations with psoriasis incidence in severity, and health care utilization.
- Cannabis Use Linked to Lower BCC Risk, No Change in Melanoma or cSCC: Studyhttps://practicaldermatology.com/news/cannabis-use-linked-to-lower-bcc-risk-no-change-in-melanoma-or-cscc/2486395/Cannabis use was linked with decreased incidince of basal cell carcinoma (BCC), but not cutaneous squamous cell carcinoma (cSCC) or malignant melanoma (MM), according to results from a newly presented poster. Researchers for t
- Lutikizumab Improves Clinical Response Rates in Moderate to Severe HS: Analysishttps://practicaldermatology.com/news/lutikizumab-shows-promise-in-hs-after-anti-tnf-failure-in-phase-2-trial/2486330/In a phase 2, double-blind, placebo-controlled randomized clinical trial, lutikizumab demonstrated efficacy signals in adults with moderate to severe hidradenitis suppurativa (HS) who had previously experienced anti–tumor necrosis factor (TNF) therapy failure.
- FDA Approves Icotrokinra for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-icotyde-for-moderate-to-severe-plaque-psoriasis/2486305/Johnson & Johnson announced that the FDA has approved ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and in pediatric patients 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phot
- ADorable-1 Trial Meets Endpoints for EBGLYSS in Children With Atopic Dermatitishttps://practicaldermatology.com/news/adorable-1-trial-meets-endpoints-for-ebglyss-in-children-with-atopic-dermatitis/2486087/Eli Lilly and Company announced positive topline results from the phase 3 ADorable-1 trial of lebrikizumab-lbkz (Ebglyss) in pediatric patients aged 6 months to 18 years with moderate-to-severe atopic dermatitis (AD), showing the therapy meeting its primary and sec
- FDA Expands Secukinumab to Adolescents With Moderate to Severe HShttps://practicaldermatology.com/news/fda-expands-secukinumab-to-adolescents-with-moderate-to-severe-hs/2486084/The US Food and Drug Administrationv (FDA) has approved secukinumab (Cosentyx, Novartis) for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa (HS), becoming the only IL-17A inhibitor approved for this group, according to a
- Review: Dermoscopic Patterns May Improve Differentiation of Acral Melanoma and Nevihttps://practicaldermatology.com/news/review-dermoscopic-patterns-may-improve-differentiation-of-acral-melanoma-and-nevi/2486062/A systematic review and meta-analysis in JAMA Dermatology provides updated evidence on dermoscopic features that differentiate acral lentiginous melanoma (ALM) from benign acral nevi. Investigators searched Embase, P